Skip to main content
See details

Reimbursement summary for angioplasty of arteries of lower extremities

This post presents an extract from our reimbursement analysis for angioplasty of arteries lower extremities using plain and drug-coated balloons (DCBs) for peripheral artery disease in England, France and Germany. Plain balloon angioplasty is reimbursement via DRG solely and DCBs are reimbursement via combination of DRG and add-on reimbursement.
See details

Swedish MTP Council recommended to wait with introduction of SpaceOAR Hydrogel and Barrigel for prostate cancer

On March 16, 2022, the Swedish Medical Technologies Product (MTP) Council released recommendations for two technologies within the Orderly introduction framework - SpaceOAR Hydrogel and Barrigel, which are used to reduce the side effects of radiotherapy in prostate cancer. The MTP Council commissioned the Swedish Dental and Pharmaceutical Benefits Agency (TLV) to perform a health economic assessment of these products in October 2021. However, TLV has not been able to make any health economic assessments because the manufacturer companies refused to participate.

MTP Council made the following recommendations to regions:

  • To wait with the use of SpaceOAR Hydrogel and Barrigel until more knowledge is available. To obtain more knowledge, the MTP Council launched a gradual introduction in four regions (Skåne, Västra Götalands, Uppsala, and Västerbotten) with a joint structured follow-up, including the national survey within the National Prostate Cancer Registry;
  • To use the products otherwise only within the clinical trials.

The Orderly framework aimed to manage the national introduction of novel technologies is working as permanent from the beginning of 2020. This is a staged process, including horizon scanning, selection of the method for evaluation, the decision on national collaboration, health economic evaluation by TLV, and recommendations by the MTP Council to regions about the introduction of the method and criteria for use.

See the full details here.

This news is just one of about 300 market access news collected by our team in the subscription services "HTA Alerts" and "Reimbursement Alerts" every two weeks from more than 80 organizations. Access our paid subscription services to stay on top of all developments specifically for your products in Europe (reimbursement news) and globally (HTA news). First EU issues of both newsletters are available for download free-of-charge.

Not ready for a subscription service? Subscribe to our free-of-charge newsletter delivered every second week to get updates about key reimbursement developments in Europe (10-12 news every two weeks).